Morgan Stanley West Coast Biotech Bus Tour: obesity, RAS oncology, HIF2α, and rare diseases emerge as the main focus

Overview

The Morgan Stanley report summarizes the main findings from its West Coast biotech bus tour and the RAS KOL dinner. The team visited more than 15 companies, including AMGN, ALMS, ARWR, BMRN, GPCR, IONS, JAZZ, MPLT, ONC, SANA, VIR, and VKTX. The report focuses on commercialization progress, clinical readouts, pipeline strategy, competitive dynamics, and valuation changes across large- and small/mid-cap biotechnology companies.

Core views

The core view is that investment opportunities in North American biotechnology continue to be driven by clinical and commercial catalysts. In obesity and metabolism, AMGN's MariTide, GPCR's Aleniglipron, and VKTX's VK2735 are all seen as important differentiated assets; in oncology, RCUS's Casdatifan, JAZZ's zanidatamab, ERAS's ERAS-0015, VIR's VIR-5500, and RAS-targeted therapies show high innovation density; in rare diseases and CNS, the growth stories for BMRN, NBIX, ACAD, and MPLT rely more on the expansion of marketed assets and key clinical readouts. The overall stance is positive, but valuation realization depends on subsequent data, regulatory milestones, and competitive dynamics.

Analysis framework

The report combines management meetings, KOL dinners, company model updates, DCF valuation, risk/reward scenario analysis, and peer competition comparisons. For RCUS, the analyst raised the Cas sales assumption and removed the discontinued dom/zim NSCLC project, lifting the target price from $20 to $22; for GPCR, the risk/reward chart shows a base-case target price of $126, a bull-case target price of $262, and a bear-case target price of $18.

Methodology notes

• Valuation methodsDCF

  Discounted cash flow valuation

  The report uses a DCF framework for RCUS and GPCR, combining peak drug sales, probability of success, R&D and SG&A assumptions, discount rates, and terminal growth rates to derive target prices.

• Risk/rewardBull/Base/Bear Case

  Bull, base, and bear scenarios

  The report shows potential upside and downside by varying clinical success rates, launch timing, peak sales, and failure assumptions.

• Clinical catalystsPipeline catalyst analysis

  Pipeline catalyst analysis

  The report focuses on events such as Phase 2, Phase 3, PDUFA, label expansion, and conference data disclosures, because these milestones can materially affect valuation and the investment narrative.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AMGN

  Attending company; Equal-weight; large biotechnology company

  Strengths

  MariTide has quarterly-dosing potential, Repatha remains underpenetrated, Uplizna early adoption is better than internal expectations, and Tepezza has room for a U.S. recovery and overseas growth.

  Weaknesses

  Key MariTide data will not arrive until later; the IRS transfer-pricing lawsuit remains unresolved.

  Comparison

  Repatha faces competition from MRK's oral enlicitide, but AMGN believes competition can expand the PCSK9 market.

  Risks

  Tax litigation, delays in obesity-drug data, competing drugs, and commercial execution.

• RCUS

  Target price raised to $22; Equal-weight

  Strengths

  Casdatifan covers 1L-3L renal cancer, PEAK 1 enrollment is progressing well, and multiple data readouts can continue to validate the drug profile.

  Weaknesses

  The share price is already under pressure relative to the base target price, and the dom/zim NSCLC project was stopped after a futility analysis.

  Comparison

  The main comparator is MRK's Welireg; LITESPARK-011 data raised the efficacy bar.

  Risks

  Clinical efficacy falls short of competitors, safety issues, competitive advances, and failure of the 1L strategy.

• GPCR / Structure Therapeutics

  Overweight; target price $126

  Strengths

  Aleniglipron's oral GLP-1 profile may have best-in-class potential in efficacy and discontinuation rates, and the 44-week Phase 2 data have not shown a plateau in weight loss.

  Weaknesses

  Valuation is highly dependent on the next Phase 3 and sales assumptions for obesity drugs.

  Comparison

  The asset targets the oral and injectable obesity/diabetes treatment market and competes with other GLP-1 and amylin programs.

  Risks

  Clinical failure, tolerability, intensifying competition, and uncertainty around launch and commercialization.

• ALMS

  Overweight; Envu and lupus data are the key focus

  Strengths

  Envu has label differentiation and partnership potential in psoriasis and lupus, and management is confident in the QD formulation.

  Weaknesses

  It remains unclear whether the FDA will impose a class-wide label; lupus studies have historically shown high placebo response rates.

  Comparison

  Management uses AZN's Saphnelo, with a 10-16% placebo-adjusted BICLA benchmark, as the efficacy reference.

  Risks

  Failure of the Phase 2b lupus data in 3Q26, label restrictions, and partnership underperformance.

• ARWR

  Overweight; Redemplo and SHTG label expansion

  Strengths

  Redemplo has exceeded 400 prescriptions early in the FCS launch, and management is cautiously optimistic that SHASTA 3/4 will meet key endpoints.

  Weaknesses

  The SHTG indication still requires Phase 3 data and label expansion.

  Comparison

  Competes with Ionis's Tryngolza, and ARWR believes Redemplo deserves a premium based on its profile.

  Risks

  Failure to meet the acute pancreatitis endpoint, pricing pressure, and competition.

• JAZZ

  Overweight; transitioning to an oncology platform

  Strengths

  Zanidatamab has FDA Priority Review, HERIZON-GEA-01 data support a potential best-in-class profile, and peak sales could exceed $2B.

  Weaknesses

  The legacy sleep business faces generic and orexin competition pressure.

  Comparison

  Oncology business growth is likely to become a more important valuation driver than the traditional sleep business.

  Risks

  Zanidatamab approval, label breadth, and adoption speed could fall short of expectations.

Key data

• Companies visited15+The report says it visited more than 15 companies over four days and held a RAS KOL dinner.
• RCUS target price change$20 -> $22DCF target price was raised, mainly driven by a higher Casdatifan sales assumption; the rating remains Equal-weight.
• RCUS current price vs base target$25.36 vs $22.00The risk/reward chart implies -13.25% downside in the base case.
• GPCR target price vs current price$126.00 vs $39.10The risk/reward chart implies +222.25% upside in the base case.
• GPCR bull/bear scenarios$262 / $18The bull case is based on a higher Aleniglipron sales assumption; the bear case assumes GSBR-1290 does not reach the market.
• ACAD cashapproximately $850MThe report believes Acadia is well capitalized and can self-fund; the key catalyst is the remlifanserin Phase 2 RADIANT readout.
• ONC 1Q26 revenueapproximately $1.5B, +35% YoYBRUKINSA revenue exceeded $1.1B, boosting confidence in the platform oncology business.
• BMRN 2026 revenue outlookapproximately $3.8-3.9BFollowing the Amicus acquisition, the company is transitioning into a multi-asset rare-disease platform.
• JAZZ zanidatamab PDUFA2026-08-25FDA Priority Review, a key milestone for Jazz's oncology transformation.
• ARWR Redemplo prescriptions>400Early FCS launch performance is strong and paves the way for SHTG label expansion.

Impact & implications

The implication for investors is that opportunities in biotechnology are clearly event-driven. In the near term, attention should be on multiple clinical and regulatory milestones in the second half of 2026; in the medium term, investors need to assess whether obesity, RAS, HIF2α, CNS, and rare-disease assets can convert early signals into verifiable commercial value. The RCUS target-price increase shows that some model assumptions have improved, but the current share price versus the base target still suggests a relatively balanced risk/reward profile; GPCR, by contrast, presents a high-upside, high-binary-risk setup.

Risks

• Clinical data may disappoint, especially if key Phase 2/Phase 3 readouts fail.
• Competitors may have better efficacy or safety, leaving the target drug insufficiently differentiated.
• Regulatory approval, PDUFA outcomes, or label expansion remain uncertain.
• Commercial launch speed, payer coverage, pricing, and physician adoption may fall short of expectations.
• Early oncology and obesity data may lack durability or sufficient sample maturity.
• Tax litigation, M&A integration, and capital requirements may affect financial flexibility.

What to watch

• ALMS Envu Phase 2b lupus data, expected in 3Q26.
• ARWR SHASTA 3/4 SHTG data, expected in 3Q26.
• IONS Tryngolza SHTG label-expansion PDUFA, date 2026-06-30.
• VKTX VK2735 Phase 1 obesity maintenance data, expected in 3Q26.
• JAZZ zanidatamab PDUFA, date 2026-08-25.
• RCUS multiple ARC-20 Casdatifan data readouts and PEAK 1 enrollment progress.
• GPCR Aleniglipron ADA conference data and Phase 3 starting-dose strategy.
• ACAD remlifanserin Phase 2 RADIANT readout, expected between August and October 2026.
• RAS-targeted drug combination therapy, tolerability, and durability data.